Capitol 982x327px

2015 ACKC
Campaign for
Research Funding

Annual campaign to get a
$15 million appropriation
for kidney cancer research

Take one minute and ask your elected officials
for their support via our Votervoice page →

Holding Hand 982x327px

Patient Guides:
Taking Charge of
Kidney Cancer

ACKC’s online pamphlets
inform and empower patients
and their caregivers

View the guides →

Researcher A 982x327px

Support ACKC

ACKC is the only major
kidney cancer grassroots
lobbying organization
raising money that goes
predominantly to fund
kidney cancer research

Donate now →

Slide background

Stay Connected

Join ACKC’s online
community of survivors,
caregivers, family and
friends by liking us
on Facebook…we’re
12,988 members strong!

ACKC on Facebook →

ACKC Point of View

  • The Cost of Cancer Medication

    Why are cancer drug prices skyrocketing? What can be done to rein in costs when drug companies are a “corporate monopoly” with the highest profits of any industry? The patient power of grass-roots groups such as ACKC may hold the solution, says Hagop Kantarjian, M.D., a leader in the in the fight to lower drug costs. Full article coming soon…


  • Concerts to Conquer Kidney Cancer

    April 27, 2015

    Join us for two-piano performances by Brenda Casey and Pat Todd in the first and second of a series of 2015 Concerts to Conquer Kidney Cancer. The concerts are fundraisers to benefit ACKC and kidney cancer research. View the program. Meet the performers. Saturday, May 16 and Sunday, May 17, 3 pm, 18 Fair Street, Guilford, CT. Donation: $40 per person, $100 per sponsor. Reservations: 203 458 1310.

  • Nivolumab Approved for Another Cancer

    March 7, 2015

    On March 4, 2015, the FDA approved the Bristo-Myers Squibb (BMS) immunotherapy drug nivolumab (Opdivo) for use in non-small cell lung cancer (NSCLC) patients for whom other drugs have failed. The approval was based on interim results in a Phase III trial testing nivolumab, at 3 mg/kg, against docetaxel, a chemotherapy drug. Nivolumb was found to have extended overall survival (OS) by three months over docetaxel, giving patients on nivolumab a median OS of 9.2… More →

  • Exposome

    February 16, 2015

    A recent segment on NPR, segment, reported about a study, involving tens of thousands of participants over a 50-year period, by Dr. Barbara Cohn from UC Berkeley looking into the effect of environmental factors on the development of breast cancer in mothers and their children. Dr. Cohn plans to map out what’s called the “exposome” (see exposome), which is a map of the exposure of an individual over his or her lifetime to various environmental and… More →

  • Rebound and Resistance in Targeted Therapies

    December 24, 2014

    John Ebos of Roswell Park Cancer Institute was granted a Career Development Award by the Congressionally Directed Medical Research Programs of the Department of Defense (DoD) to study, using a pre-clinical model, rebound and resistance to targeted therapies in RCC. This two-year grant was funded at $602,996 in Fiscal Year 2013 (the latest award year). This project is designed to answer a number of important questions, in regard to targeted therapy, that have not been… More →

  • Launching New Website

    December 7, 2014

    Today ACKC is launching its new website, updating older material and adding new content, which we will continue to do in the future. Two new features on the Homepage are “News” and “Point of View” essays. News will commence with two articles, one highlighting two studies on the use of sunitinib (Sutent) in the elderly, and a second article featuring Maria Czyzyk-Krzeska from the University of Cincinnati. Maria is one of the two winners of… More →